SAN ANTONIO — Several types of anti-obesity medications (AOMs), including glucagon-like peptide 1s (GLP-1s), are associated ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

Summary: Scientists have identified BHB-Phe, a natural compound produced by the body, that regulates appetite and body weight ...

Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

A recent study found semaglutide – the drug known as Ozempic – can improve knee pain in people with obesity and ...

Surging demand for a new generation of highly effective anti-obesity medications is creating interest in compounded versions of these medications.

A new study examining a large sample of privately insured patients with obesity found that use of drugs such as Ozempic and Wegovy as anti-obesity medications more than doubled from 2022 to 2023.

That’s according to a clinical trial conducted in 11 countries — the first of its kind to show that one of the wave of ...

Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by ...